- Home
- TRIP vs JANX Comparison
TRIP vs JANX Comparison
Compare TRIP & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- JANX
- Stock Information
- Founded
- TRIP 2000
- JANX 2017
- Country
- TRIP United States
- JANX United States
- Employees
- TRIP N/A
- JANX N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- JANX Health Care
- Exchange
- TRIP Nasdaq
- JANX Nasdaq
- Market Cap
- TRIP 1.8B
- JANX 1.7B
- IPO Year
- TRIP 2011
- JANX 2021
- Fundamental
- Price
- TRIP $15.06
- JANX $29.41
- Analyst Decision
- TRIP Hold
- JANX Strong Buy
- Analyst Count
- TRIP 9
- JANX 10
- Target Price
- TRIP $16.25
- JANX $77.40
- AVG Volume (30 Days)
- TRIP 2.8M
- JANX 1.1M
- Earning Date
- TRIP 11-06-2025
- JANX 11-06-2025
- Dividend Yield
- TRIP N/A
- JANX N/A
- EPS Growth
- TRIP 124.53
- JANX N/A
- EPS
- TRIP 0.59
- JANX N/A
- Revenue
- TRIP $1,891,000,000.00
- JANX $10,000,000.00
- Revenue This Year
- TRIP $7.41
- JANX N/A
- Revenue Next Year
- TRIP $7.15
- JANX $89.91
- P/E Ratio
- TRIP $25.54
- JANX N/A
- Revenue Growth
- TRIP 4.25
- JANX N/A
- 52 Week Low
- TRIP $10.43
- JANX $21.73
- 52 Week High
- TRIP $20.16
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- TRIP 42.64
- JANX 58.15
- Support Level
- TRIP $14.71
- JANX $26.96
- Resistance Level
- TRIP $16.04
- JANX $29.53
- Average True Range (ATR)
- TRIP 0.79
- JANX 2.10
- MACD
- TRIP -0.04
- JANX 0.00
- Stochastic Oscillator
- TRIP 14.33
- JANX 67.36
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.